Safety of Hydroxychloroquine, Favipiravir, and the Combination of Lopinavir and Ritonavir in the Treatment of the “First Wave” of the New Coronavirus Infection COVID-19
The review compares individual case safety reports (ICSRs) for hydroxychloroquine, favipiravir, and the lopinavir/ ritonavir combination registered in the VigiBase global database during 6 months in 2019 and the same period in 2020 which coincides with the global “first wave”. The aim of the study w...
Saved in:
Main Author: | B. K. Romanov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)
2020-09-01
|
Series: | Регуляторные исследования и экспертиза лекарственных средств |
Subjects: | |
Online Access: | https://www.vedomostincesmp.ru/jour/article/view/334 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The efficacy of nelfinavir and lopinavir/ritonavir in the treatment of HIV-infected pediatric patients
by: V. B. Denisenko,, et al.
Published: (2018-12-01) -
Lopinavir/ritonavir as part of schemes of HAARt in HIV-positive pregnant women and women of reproductive age: the dynamics of clinical and immunological and virological indicators
by: A. B. Konkova-Reidman, et al.
Published: (2015-04-01) -
Experience in Using Antiviral Agents for the Treatment of Novel Coronavirus Infection (COVID-19) in Kyrgyzstan
by: A. A. Zurdinova, et al.
Published: (2021-12-01) -
A Model for Predicting the Risk of Developing Drug-Induced Liver Injury During Therapy with Favipiravir
by: Yu. V. Shevchuk, et al.
Published: (2025-02-01) -
The role of pharmacogenetics in Efficacy and safety of protease inhibitor based therapy in human immunodeficiency virus type (HIV) infection.
by: A. Yu. Sambyalova, et al.
Published: (2021-12-01)